"The FDA granted expedited approval to orforglipron, a GLP-1 drug that works similarly to widely used injectable treatments by mimicking a natural hormone that helps regulate appetite and feelings of fullness."
"We believe Foundayo can help level the playing field for those living with obesity or who are overweight and living with weight-related complications."
"Unlike the Wegovy pill, which must be taken first thing in the morning on an empty stomach, this medication can be taken at any point during the day without regard to meals."
"The starting dose is projected to cost around $149 per month for those paying without insurance, similar to the Wegovy pill."
The FDA approved orforglipron, branded as Foundayo, a new oral weight-loss medication from Eli Lilly. This drug is the second GLP-1 pill approved recently, following Novo Nordisk's Wegovy. Orforglipron mimics a natural hormone to regulate appetite and fullness. Many eligible patients do not use GLP-1 treatments due to access and stigma. Foundayo can be taken any time of day, unlike Wegovy. The starting cost is about $149 monthly, with potential Medicare coverage proposed for certain patients this summer.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]